Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Capital Leases (2024 - 2025)

Evommune (EVMN) has disclosed Capital Leases for 2 consecutive years, with $181000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Leases fell 66.17% to $181000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $181000.0, a 66.17% decrease, with the full-year FY2025 number at $181000.0, down 66.17% from a year prior.
  • Capital Leases was $181000.0 for Q4 2025 at Evommune, down from $535000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $535000.0 in Q4 2024 to a low of $181000.0 in Q4 2025.